Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?

by Clinical Neuropsychologist Online | Monday, October 12, 2026 | Dementia

Abstract In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti-amyloid drugs for Alzheimer’s disease are the first approved drugs; however, the impact of co‑pathology on the...

Cross‐cohort NULISAseq identifies tau‐anchored CSF and plasma‐specific signatures across the amyloid‐positive Alzheimer’s disease

by Clinical Neuropsychologist Online | Monday, October 12, 2026 | Dementia

Abstract INTRODUCTION ATN-stratified cerebrospinal fluid (CSF) proteomic signals may partly reflect classifier tau immunoassays; reproducible non-tau signals and CSF–plasma differences remain unclear. METHODS We profiled CSF from 60 A+ Beijing patients with...

ApoE lipidation state directs immunometabolic reprogramming of human microglia

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION ApoE ε4 is the strongest genetic risk factor for Alzheimer’s disease (AD). Emerging evidence suggests that ApoE4 increases AD risk by disrupting microglial metabolism and function. However, whether ApoE lipidation state contributes to...

The effects of improved access to diabetes medications on risk of Alzheimer’s disease and related dementias

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION Diabetes is associated with elevated risk of Alzheimer’s disease and related dementias (ADRD). Disease management with pharmaceutical therapies may mitigate this increased risk, but access and use of diabetes therapies are limited,...

Data‑driven cognitive composites predict Aβ‑related decline and progression to MCI: the ADOPIC study

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION Cognitive composites offer greater sensitivity to amyloid beta (Aβ)-related decline compared to individual tests for tracking longitudinal cognitive change. We developed and validated data-driven composites from the harmonized Alzheimer’s...

Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population‐based cohort study

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION Effective disease-modifying therapies remain unavailable for neurodegenerative diseases (NDDs). Tyrosine kinase inhibitors (TKIs) indicated for chronic myeloid leukemia (CML) have been hypothesized to modulate the pathological mechanisms...